A Study to Evaluate the Safety, Tolerability, Immunogenicity and Vaccine-like Viral Shedding of MEDI-534, Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3), in Healthy 6 to <24 Month-old Children and in 2 Month-old Infants
NCT ID: NCT00686075
Last Updated: 2014-09-26
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1/PHASE2
1338 participants
INTERVENTIONAL
2008-06-30
2012-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Tolerability Study to Evaluate MEDI-534 in Children 6 to < 24 Months of Age
NCT00493285
Study to Evaluate the Safety of MEDI-534 Vaccine Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3) in Healthy Children
NCT00345670
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety of MEDI-559 in Healthy 1 to <24 Month-Old Children
NCT00767416
Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seronegative Children 6-36 Months
NCT04909021
Study of the Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seropositive Children
NCT04444284
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
MEDI-534, Cohort 1
Participants aged 6 to less than (\<) 24 months will receive MEDI-534, 10\^5 median tissue culture infectious dose (TCID50) by intranasal route at Month 0, 2, and 4.
MEDI-534, Cohort 1
Participants aged 6 to less than (\<) 24 months will receive MEDI-534, 10\^5 median tissue culture infectious dose (TCID50) by intranasal route at Month 0, 2, and 4.
Placebo, Cohort 1
Participants aged 6 to \<24 months will receive placebo matched to MEDI-534, 10\^5 TCID50 by intranasal route at Month 0, 2, and 4.
Placebo, Cohort 1
Participants aged 6 to \<24 months will receive placebo matched to MEDI-534, 10\^5 TCID50 by intranasal route at Month 0, 2, and 4.
MEDI-534, Cohort 2
Participants aged 6 to \<24 months will receive MEDI-534, 10\^6 TCID50 by intranasal route at Month 0, 2, and 4.
MEDI-534, Cohort 2
Participants aged 6 to \<24 months will receive MEDI-534, 10\^6 TCID50 by intranasal route at Month 0, 2, and 4.
Placebo, Cohort 2
Participants aged 6 to \<24 months will receive placebo matched to MEDI-534, 10\^6 TCID50 by intranasal route at Month 0, 2, and 4.
Placebo, Cohort 2
Participants aged 6 to \<24 months will receive placebo matched to MEDI-534, 10\^6 TCID50 by intranasal route at Month 0, 2, and 4.
MEDI-534, Cohort 3
Participants aged 2 months will receive MEDI-534, 10\^4 TCID50 by intranasal route at Month 0, 2, and 4.
MEDI-534, Cohort 3
Participants aged 2 months will receive MEDI-534, 10\^4 TCID50 by intranasal route at Month 0, 2, and 4.
Placebo, Cohort 3
Participants aged 2 months will receive placebo matched to MEDI-534, 10\^4 TCID50 by intranasal route at Month 0, 2, and 4.
Placebo, Cohort 3
Participants aged 2 months will receive placebo matched to MEDI-534, 10\^4 TCID50 by intranasal route at Month 0, 2, and 4.
MEDI-534, Cohort 4
Participants aged 2 months will receive MEDI-534, 10\^5 TCID50 by intranasal route at Month 0, 2, and 4.
MEDI-534, Cohort 4
Participants aged 2 months will receive MEDI-534, 10\^5 TCID50 by intranasal route at Month 0, 2, and 4.
Placebo, Cohort 4
Participants aged 2 months will receive placebo matched to MEDI-534, 10\^5 TCID50 by intranasal route at Month 0, 2, and 4.
Placebo, Cohort 4
Participants aged 2 months will receive placebo matched to MEDI-534, 10\^5 TCID50 by intranasal route at Month 0, 2, and 4.
MEDI-534, Cohort 5
Participants aged 2 months will receive MEDI-534, 10\^6 TCID50 by intranasal route at Month 0, 2, and 4.
MEDI-534, Cohort 5
Participants aged 2 months will receive MEDI-534, 10\^6 TCID50 by intranasal route at Month 0, 2, and 4.
Placebo, Cohort 5
Participants aged 2 months will receive placebo matched to MEDI-534, 10\^6 TCID50 by intranasal route at Month 0, 2, and 4.
Placebo, Cohort 5
Participants aged 2 months will receive placebo matched to MEDI-534, 10\^6 TCID50 by intranasal route at Month 0, 2, and 4.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MEDI-534, Cohort 1
Participants aged 6 to less than (\<) 24 months will receive MEDI-534, 10\^5 median tissue culture infectious dose (TCID50) by intranasal route at Month 0, 2, and 4.
Placebo, Cohort 1
Participants aged 6 to \<24 months will receive placebo matched to MEDI-534, 10\^5 TCID50 by intranasal route at Month 0, 2, and 4.
MEDI-534, Cohort 2
Participants aged 6 to \<24 months will receive MEDI-534, 10\^6 TCID50 by intranasal route at Month 0, 2, and 4.
Placebo, Cohort 2
Participants aged 6 to \<24 months will receive placebo matched to MEDI-534, 10\^6 TCID50 by intranasal route at Month 0, 2, and 4.
MEDI-534, Cohort 3
Participants aged 2 months will receive MEDI-534, 10\^4 TCID50 by intranasal route at Month 0, 2, and 4.
Placebo, Cohort 3
Participants aged 2 months will receive placebo matched to MEDI-534, 10\^4 TCID50 by intranasal route at Month 0, 2, and 4.
MEDI-534, Cohort 4
Participants aged 2 months will receive MEDI-534, 10\^5 TCID50 by intranasal route at Month 0, 2, and 4.
Placebo, Cohort 4
Participants aged 2 months will receive placebo matched to MEDI-534, 10\^5 TCID50 by intranasal route at Month 0, 2, and 4.
MEDI-534, Cohort 5
Participants aged 2 months will receive MEDI-534, 10\^6 TCID50 by intranasal route at Month 0, 2, and 4.
Placebo, Cohort 5
Participants aged 2 months will receive placebo matched to MEDI-534, 10\^6 TCID50 by intranasal route at Month 0, 2, and 4.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
6 to less than (\<) 24 months (more than \[\>\] 6 months of age and not yet reached their 2nd year birthday), Cohorts 1 and 2 2 months (+/- 4 weeks), Cohorts 3, 4, and 5
* Cohorts 1 and 2 only: Subject is seronegative to both Respiratory Syncytial Virus (RSV) and human Parainfluenza Virus Type 3 (hPIV3) at Screening
* Subject whose gestational age was greater than or equal to (\>=) 36 weeks
* Subject is in general good health with normal growth (that is, body weight greater than (\>) third percentile per world health organization \[WHO\] simplified weight-per-age field tables
* Subject's legal representative is available by telephone
* Written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization (if applicable) obtained from the subject's legal representative
* Subject's legal representative is able to understand and comply with the requirements of the protocol as judged by the investigator
* Subject is available to complete the follow-up period 1-year after receipt of the first dose of study vaccine
* Subject's legal representative must be willing and able to bring the subject to the study site for evaluation of respiratory illness in accordance with the protocol.
Exclusion Criteria
* Moderate or severe nasal congestion that in the investigator's opinion could interfere with intranasal delivery of study vaccine
* Acute illness (defined as the presence of moderate or severe signs and symptoms) at the time of randomization
* Any drug therapy (chronic or other) within 7 days prior to randomization or expected receipt through the protocol-specified blood collection 28 days after each study vaccine dosing, except that infrequent use of over-the-counter medications for the systemic treatment of common childhood symptoms (that is, pain relievers, decongestants or cough suppressants) are permitted according to the judgment of the investigator
* Any current or expected receipt of immunosuppressive agents including steroids (\>=2 milligram per kilogram \[mg/kg\] per day of prednisone or its equivalent, or \>=20 milligram per day \[mg/day\] if the subject weighs \>10 kilogram \[kg\], given daily or on alternate days for \>=14 days); children in this category should not receive study vaccine until immunosuppressive agents including corticosteroid therapy have been discontinued for \>=30 days; the use of topical steroids is permitted according to the judgment of the investigator
* History of receipt of blood transfusion or expected receipt through the protocol-specified blood collection at 28 days after final study dosing
* History of receipt of immunoglobulin products or expected receipt through the protocol-specified blood collection at 28 days after final study dosing
* Receipt of any investigational drug within 60 days prior to randomization or expected receipt through 180 days after final study dosing
* Receipt of any live virus vaccine (excluding oral polio vaccine and rotavirus vaccine) within 28 days prior to randomization or expected receipt within a 28-day window around any study vaccine dose
* Receipt of any inactivated (that is, non-live) vaccine or oral polio vaccine or rotavirus vaccine within 14 days prior to randomization or expected receipt within a 14-day window around any study vaccine dose
* Known or suspected immunodeficiency, including human immunodeficiency virus (HIV) infection
* Expected to be living in the same home or enrolled in the same classroom at day care with infants \<6 months within 28 days after each dose
* Living in a household with another child who is concurrently enrolled in a study of a live viral vaccine (including this study)
* Expected contact with a pregnant caregiver within 28 days after each dose
* A household contact who is immunocompromised; the subject should also avoid close contact with immunocompromised individuals for at least 28 days after any study vaccine dose
* Expected household contact within 28 days after each dose with a health care provider for immunocompromised subjects or who is a day care provider for infants under the age of 6 months
* History of allergic reaction to any component of the study vaccine
* Previous medical history, or evidence, of an intercurrent or chronic illness that, in the opinion of the investigator, may compromise the safety of the subject
* Known or suspected active or chronic hepatitis infection
* History of medical diagnosis of asthma, reactive airway disease, wheezing requiring medication, cystic fibrosis, bronchopulmonary dysplasia, chronic pulmonary disease, medically confirmed apnea, hospitalization for respiratory illness or mechanical ventilation for respiratory illness (excludes elective mechanical ventilation during surgery for subjects in Cohorts 1 and 2)
* Family member or household contact who is an employee of the research center or otherwise involved with the conduct of the study
* Any condition that, in the opinion of the investigator, might interfere with study vaccine evaluation.
2 Months
23 Months
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
MedImmune LLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Elissa Malkin, D.O.
Role: STUDY_DIRECTOR
MedImmune LLC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Mobile, Alabama, United States
Research Site
Bentonville, Arkansas, United States
Research Site
Little Rock, Arkansas, United States
Research Site
Anaheim, California, United States
Research Site
Anaheim, California, United States
Research Site
Bell Gardens, California, United States
Research Site
Downey, California, United States
Research Site
Lakewood, California, United States
Research Site
Long Beach, California, United States
Research Site
Paramount, California, United States
Research Site
San Diego, California, United States
Research Site
West Covina, California, United States
Research Site
Thornton, Colorado, United States
Research Site
Gainesville, Florida, United States
Research Site
Tampa, Florida, United States
Research Site
Dalton, Georgia, United States
Research Site
Chicago, Illinois, United States
Research Site
Kansas City, Kansas, United States
Research Site
Topeka, Kansas, United States
Research Site
Lexington, Kentucky, United States
Research Site
Paducah, Kentucky, United States
Research Site
Shreveport, Louisiana, United States
Research Site
Saint Paul, Minnesota, United States
Research Site
Bridgeton, Missouri, United States
Research Site
Omaha, Nebraska, United States
Research Site
Omaha, Nebraska, United States
Research Site
Las Vegas, Nevada, United States
Research Site
Brooklyn, New York, United States
Research Site
Johnson City, New York, United States
Research Site
Lake Success, New York, United States
Research Site
Stony Brook, New York, United States
Research Site
Syracuse, New York, United States
Research Site
New Bern, North Carolina, United States
Research Site
Cincinnati, Ohio, United States
Research Site
Gresham, Oregon, United States
Research Site
Pittsburgh, Pennsylvania, United States
Research Site
Sellersville, Pennsylvania, United States
Research Site
Jackson, Tennessee, United States
Research Site
Amarillo, Texas, United States
Research Site
Dallas, Texas, United States
Research Site
Houston, Texas, United States
Research Site
Poteet, Texas, United States
Research Site
San Antonio, Texas, United States
Research Site
San Antonio, Texas, United States
Research Site
San Antonio, Texas, United States
Research Site
Tomball, Texas, United States
Research Site
Layton, Utah, United States
Research Site
Orem, Utah, United States
Research Site
St. George, Utah, United States
Research Site
Midlothian, Virginia, United States
Research Site
Huntington, West Virginia, United States
Research Site
Garran, Australian Capital Territory, Australia
Research Site
Herston, Queensland, Australia
Research Site
North Adelaide, South Australia, Australia
Research Site
Subiaco, Western Australia, Australia
Research Site
Passo Fundo-RS, Rio Grande do Sul, Brazil
Research Site
São Paulo, São Paulo, Brazil
Research Site
Porto Alegre - RS, , Brazil
Research Site
Porto Alegre/RS, , Brazil
Research Site
Ribeirao Preto - SP, , Brazil
Research Site
Sao Paulo - SP, , Brazil
Research Site
São Paulo, , Brazil
Research Site
Brampton, Ontario, Canada
Research Site
Saskatoon, Saskatchewan, Canada
Research Site
Helsinki, , Finland
Research Site
Järvenpää, , Finland
Research Site
Kokkola, , Finland
Research Site
Kuopio, , Finland
Research Site
Lahti, , Finland
Research Site
Oulu, , Finland
Research Site
Pori, , Finland
Research Site
Tampere, , Finland
Research Site
Turku, , Finland
Research Site
Berlin, , Germany
Research Site
Freiburg im Breisgau, , Germany
Research Site
Mainz, , Germany
Research Site
Netanya, , Israel
Research Site
Johannesburg, Gauteng, South Africa
Research Site
Pretoria, Gauteng, South Africa
Research Site
Belle Ville Cape Town, Western Cape, South Africa
Research Site
Cape Town, Western Cape, South Africa
Research Site
Almería, Andalusia, Spain
Research Site
Almería, Andalusia, Spain
Research Site
Almería, Andalusia, Spain
Research Site
Jerez de la Frontera, Andalusia, Spain
Research Site
Donostia / San Sebastian, Basque Country, Spain
Research Site
Barcelona, Catalonia, Spain
Research Site
Santiago de Compostela, Galicia, Spain
Research Site
Madrid, Madrid, Spain
Research Site
Madrid, Madrid, Communidad de, Spain
Research Site
Málaga, Málaga, Spain
Research Site
Catarroja, Valencia, Spain
Research Site
La Eliana, Valencia, Valencia, Spain
Research Site
Valencia, Valencia, Spain
Research Site
Valencia, Valencia, Spain
Research Site
Valencia, Valencia, Spain
Research Site
Valencia, Valencia, Spain
Research Site
Esplugues de Llobregat, , Spain
Research Site
Valencia, , Spain
Research Site
Valencia, , Spain
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Yang CF, Wang CK, Malkin E, Schickli JH, Shambaugh C, Zuo F, Galinski MS, Dubovsky F; Study Group; Tang RS. Implication of respiratory syncytial virus (RSV) F transgene sequence heterogeneity observed in Phase 1 evaluation of MEDI-534, a live attenuated parainfluenza type 3 vectored RSV vaccine. Vaccine. 2013 Jun 10;31(26):2822-7. doi: 10.1016/j.vaccine.2013.04.006. Epub 2013 Apr 16.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MI-CP178
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.